Skip to contentpdufa.bio

dabogratinib (TYRA-300)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

dabogratinib (TYRA-300) is a Tyra Biosciences, Inc. program in low-grade upper tract urothelial carcinoma (LG-UTUC). Its next catalyst is a Readout in Q4 2027.

TYRA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Low-grade upper tract urothelial carcinoma (LG-UTUC). Sponsor: Tyra Biosciences, Inc. (TYRA). Review status: Phase 2a/b in low-grade upper tract urothelial carcinoma; first patient dosed. Company guides initial results in 2027. We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027TYRA

Specialist biotech funds holding TYRA, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management12,198,625$266.8 millionfiled November 16, 2026
BVF Inc.4,215,886$92.2 millionfiled November 16, 2026
Baker Bros. Advisors10,607$231,975filed November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is dabogratinib (TYRA-300)'s next FDA decision or readout?

The next tracked catalyst for dabogratinib (TYRA-300) is a Readout in Q4 2027.

What happened at dabogratinib (TYRA-300)'s most recent FDA decision?

No FDA decision for dabogratinib (TYRA-300) is in our archive yet.

What is dabogratinib (TYRA-300) used for?

In our records dabogratinib (TYRA-300) is under review or in development for Low-grade upper tract urothelial carcinoma (LG-UTUC).

Who makes dabogratinib (TYRA-300)?

Tyra Biosciences, Inc. (TYRA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.